{"id":"https://openalex.org/W2599676000","doi":"https://doi.org/10.2217/ebo.11.327","title":"Pathophysiology and drug targets in metastatic colorectal cancer","display_name":"Pathophysiology and drug targets in metastatic colorectal cancer","publication_year":2011,"publication_date":"2011-11-01","ids":{"openalex":"https://openalex.org/W2599676000","doi":"https://doi.org/10.2217/ebo.11.327","mag":"2599676000"},"language":"en","primary_location":{"id":"doi:10.2217/ebo.11.327","doi":"https://doi.org/10.2217/ebo.11.327","is_oa":false,"landing_page_url":"https://doi.org/10.2217/ebo.11.327","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacological Advances in Metastatic Colorectal Cancer Management","raw_type":"other"},"volume":{"id":"https://openalex.org/W2486710555","display_name":"Pharmacological Advances in Metastatic Colorectal Cancer Management"},"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086781190","display_name":"Autumn J. McRee","orcid":"https://orcid.org/0000-0002-0475-1579","observed_orcids":["https://orcid.org/0000-0002-0475-1579","https://orcid.org/0009-0005-9153-2006","https://orcid.org/0000-0003-2868-1576"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Autumn McRee","raw_affiliation_strings":["Autumn McRee is Assistant Professor of Medicine within the Division of Hematology/Oncology as part of the Gastrointestinal Oncology Program at the University of North Carolina (UNC) at Chapel Hill (NC, USA). She completed her hematology/oncology fellowship at UNC. Prior to her fellowship, she completed an Internal Medicine residency at Vanderbilt University (TN, USA). She received her medical degree from the University of Texas Health Science Center (TX, USA) and her undergraduate degree in molecular","Autumn McRee is Assistant Professor of Medicine within the Division of Hematology/Oncology as part of the Gastrointestinal Oncology Program at the University of North Carolina (UNC) at Chapel Hill (NC, USA). She completed her hematology/oncology fellowship at UNC. Prior to her fellowship, she completed an Internal Medicine residency at Vanderbilt University (TN, USA). She received her medical degree from the University of Texas Health Science Center (TX, USA) and her undergraduate degree in molecular biology from Vanderbilt University. Her clinical interests are in the multidisciplinary care of patients with gastrointestinal malignancies. Specifically, she has an interest in patients with colorectal and pancreatic cancer with a focus on clinical trials designed to investigate new promising treatments for these patients as well as incorporating correlative science studies into these trials that will help determine biomarkers of response and resistance to targeted therapies based on tumor biology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autumn McRee is Assistant Professor of Medicine within the Division of Hematology/Oncology as part of the Gastrointestinal Oncology Program at the University of North Carolina (UNC) at Chapel Hill (NC, USA). She completed her hematology/oncology fellowship at UNC. Prior to her fellowship, she completed an Internal Medicine residency at Vanderbilt University (TN, USA). She received her medical degree from the University of Texas Health Science Center (TX, USA) and her undergraduate degree in molecular","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I200719446"]},{"raw_affiliation_string":"Autumn McRee is Assistant Professor of Medicine within the Division of Hematology/Oncology as part of the Gastrointestinal Oncology Program at the University of North Carolina (UNC) at Chapel Hill (NC, USA). She completed her hematology/oncology fellowship at UNC. Prior to her fellowship, she completed an Internal Medicine residency at Vanderbilt University (TN, USA). She received her medical degree from the University of Texas Health Science Center (TX, USA) and her undergraduate degree in molecular biology from Vanderbilt University. Her clinical interests are in the multidisciplinary care of patients with gastrointestinal malignancies. Specifically, she has an interest in patients with colorectal and pancreatic cancer with a focus on clinical trials designed to investigate new promising treatments for these patients as well as incorporating correlative science studies into these trials that will help determine biomarkers of response and resistance to targeted therapies based on tumor biology","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I200719446"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011034688","display_name":"Howard L. McLeod","orcid":"https://orcid.org/0000-0002-9004-9232","observed_orcids":["https://orcid.org/0000-0002-9004-9232"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard L McLeod","raw_affiliation_strings":["Howard L McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina (NC, USA). He holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Cancer Center. Following training in pharmacy and clinical pharmacology in Seattle and Philadelphia, he completed a clinical research fellowship in cancer clinical pharmacology at St Jude Children\u2019s Research","Howard L McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina (NC, USA). He holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Cancer Center. Following training in pharmacy and clinical pharmacology in Seattle and Philadelphia, he completed a clinical research fellowship in cancer clinical pharmacology at St Jude Children's Research Hospital, followed by a cancer pharmacology postdoctoral fellowship at the Beatson Oncology Centre at the University of Glasgow (UK). In 2006, he moved to North Carolina to start the UNC pharmacogenomics effort. He is Chair of the NHGRI eMERGE Network External Scientific Panel and is a member of the US FDA Committee on Clinical Pharmacology. He is a member of the NIH NHGRI Advisory Council. He also directs the Pharmacogenetics for Every Nation Initiative, which aims to help developing countries use genetic information to improve National Drug Formulary decisions. He has published over 400 peer-reviewed papers on pharmacogenomics, applied therapeutics or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance individualized medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Howard L McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina (NC, USA). He holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Cancer Center. Following training in pharmacy and clinical pharmacology in Seattle and Philadelphia, he completed a clinical research fellowship in cancer clinical pharmacology at St Jude Children\u2019s Research","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"Howard L McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina (NC, USA). He holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Cancer Center. Following training in pharmacy and clinical pharmacology in Seattle and Philadelphia, he completed a clinical research fellowship in cancer clinical pharmacology at St Jude Children's Research Hospital, followed by a cancer pharmacology postdoctoral fellowship at the Beatson Oncology Centre at the University of Glasgow (UK). In 2006, he moved to North Carolina to start the UNC pharmacogenomics effort. He is Chair of the NHGRI eMERGE Network External Scientific Panel and is a member of the US FDA Committee on Clinical Pharmacology. He is a member of the NIH NHGRI Advisory Council. He also directs the Pharmacogenetics for Every Nation Initiative, which aims to help developing countries use genetic information to improve National Drug Formulary decisions. He has published over 400 peer-reviewed papers on pharmacogenomics, applied therapeutics or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance individualized medicine","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"6","last_page":"16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":1.0},{"id":"https://openalex.org/keywords/pathophysiology","display_name":"pathophysiology","score":0.9440000057220459},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.9610000252723694},{"id":"https://openalex.org/keywords/therapeutic-agents","display_name":"therapeutic agents","score":0.703000009059906},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.8970000147819519},{"id":"https://openalex.org/keywords/personalized-medicine","display_name":"personalized medicine","score":0.7490000128746033},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6449999809265137},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6290000081062317},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.46000000834465027},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.953000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7079261541366577},{"id":"https://openalex.org/C170734499","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenomics","level":2,"score":0.6148766875267029},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5717009902000427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5705117583274841},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5511085391044617},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5119365453720093},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.45792919397354126},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4289679527282715},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.3027271628379822},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.17042747139930725}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2217/ebo.11.327","doi":"https://doi.org/10.2217/ebo.11.327","is_oa":false,"landing_page_url":"https://doi.org/10.2217/ebo.11.327","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacological Advances in Metastatic Colorectal Cancer Management","raw_type":"other"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W1586129343","https://openalex.org/W1633168121","https://openalex.org/W1863898801","https://openalex.org/W1968014316","https://openalex.org/W1969730641","https://openalex.org/W1972248724","https://openalex.org/W1984328540","https://openalex.org/W1987746359","https://openalex.org/W2002959795","https://openalex.org/W2012063336","https://openalex.org/W2031436799","https://openalex.org/W2044970916","https://openalex.org/W2063095922","https://openalex.org/W2069320022","https://openalex.org/W2095201384","https://openalex.org/W2095822339","https://openalex.org/W2096096300","https://openalex.org/W2106787323","https://openalex.org/W2106789440","https://openalex.org/W2116846790","https://openalex.org/W2119347977","https://openalex.org/W2122730895","https://openalex.org/W2139687160","https://openalex.org/W2144425748","https://openalex.org/W2147270594","https://openalex.org/W2150487692","https://openalex.org/W2152215024","https://openalex.org/W2157019123","https://openalex.org/W2157963272","https://openalex.org/W2164008484","https://openalex.org/W2468387208","https://openalex.org/W2589790637"],"related_works":["https://openalex.org/W1998771727","https://openalex.org/W1600066988","https://openalex.org/W2083276575","https://openalex.org/W2313528637","https://openalex.org/W2218546288","https://openalex.org/W2985131423","https://openalex.org/W2256447909","https://openalex.org/W2945044089","https://openalex.org/W4385771034","https://openalex.org/W2330256487"],"abstract_inverted_index":{"Colorectal":[0],"cancer":[1,53,123,144],"is":[2],"the":[3,41,55,64,78,116,125,133,147],"third":[4],"most":[5],"common":[6],"malignancy":[7],"worldwide,":[8],"with":[9,24,27,35,50,63,90,132],"over":[10,54],"650,000":[11],"new":[12],"diagnoses":[13],"each":[14],"year":[15],"[1].":[16],"Approximately":[17],"a":[18,28,97,136],"fifth":[19],"of":[20,31,87],"patients":[21,32,49,91,145],"initially":[22,33],"present":[23],"metastatic":[25,42,51,121,142],"disease":[26,37],"major":[29],"portion":[30],"diagnosed":[34],"localized":[36],"eventually":[38],"recurring":[39],"in":[40,84,146],"setting.":[43],"The":[44],"treatment":[45,95],"advances":[46],"made":[47],"for":[48,120,135],"colorectal":[52,122,143],"past":[56],"40":[57],"years":[58],"have":[59,129],"dramatically":[60],"improved":[61],"outcomes":[62],"median":[65],"survival":[66],"extending":[67],"to":[68,101,140],"almost":[69],"2":[70],"years.":[71],"However,":[72],"all":[73],"therapies,":[74,82],"including":[75],"chemotherapeutics":[76],"and":[77,89,109,124],"more":[79,137],"novel":[80],"targeted":[81],"result":[83],"varying":[85],"amounts":[86],"toxicity":[88],"being":[92],"afforded":[93],"lengthier":[94],"courses,":[96],"crucial":[98],"need":[99],"exists":[100],"develop":[102],"consistent":[103],"ways":[104],"physicians":[105],"can":[106],"predict":[107],"response":[108],"prevent":[110],"undue":[111],"toxicity.":[112],"This":[113],"chapter":[114],"summarizes":[115],"approved":[117],"therapeutic":[118],"agents":[119],"various":[126],"biomarkers":[127],"that":[128],"been":[130],"evaluated":[131],"hope":[134],"personalized":[138],"approach":[139],"treating":[141],"future.":[148]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-04-07T00:00:00"}